カテゴリ： 世界, 医療/バイオ, Market Monitor Global

閉経後骨粗鬆症治療のグローバル市場展望 2023年-2029年：ビスホスホネート、ビタミンD3、エストロゲンアゴニスト/アンタゴニスト、ホルモン補充療法、副甲状腺ホルモン療法、その他

■ 英語タイトル：Postmenopausal Osteoporosis Treatment Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート（データ管理コード：MMG23DC16196）■ 発行会社/調査会社：Market Monitor Global
■ 商品コード：MMG23DC16196
■ 発行日：2023年12月
■ 調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野：医療
■ ページ数：62
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[閉経後骨粗鬆症治療のグローバル市場展望 2023年-2029年：ビスホスホネート、ビタミンD3、エストロゲンアゴニスト/アンタゴニスト、ホルモン補充療法、副甲状腺ホルモン療法、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査レポートは次の情報を含め、世界の閉経後骨粗鬆症治療市場規模と予測を収録しています。・世界の閉経後骨粗鬆症治療市場：売上、2018年-2023年、2024年-2029年
・世界の閉経後骨粗鬆症治療市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の閉経後骨粗鬆症治療市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「ビスホスホネート」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

閉経後骨粗鬆症治療のグローバル主要企業は、Teva Pharmaceuticals Industries Ltd.、 Pfizer Inc.、 Merck & Co.、 Novartis AG、 Eli Lilly and Company、 AbbVie (Allergan plc.)、 F. Hoffmann-La Roche Ltd.、 Cipla Inc.、 Amgen Inc.などです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、閉経後骨粗鬆症治療のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の閉経後骨粗鬆症治療市場：タイプ別、2018年-2023年、2024年-2029年
世界の閉経後骨粗鬆症治療市場：タイプ別市場シェア、2022年
・ビスホスホネート、ビタミンD3、エストロゲンアゴニスト/アンタゴニスト、ホルモン補充療法、副甲状腺ホルモン療法、その他

世界の閉経後骨粗鬆症治療市場：用途別、2018年-2023年、2024年-2029年
世界の閉経後骨粗鬆症治療市場：用途別市場シェア、2022年
・病院薬局、小売薬局、その他

世界の閉経後骨粗鬆症治療市場：地域・国別、2018年-2023年、2024年-2029年
世界の閉経後骨粗鬆症治療市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における閉経後骨粗鬆症治療のグローバル売上、2018年-2023年
・主要企業における閉経後骨粗鬆症治療のグローバル売上シェア、2022年
・主要企業における閉経後骨粗鬆症治療のグローバル販売量、2018年-2023年
・主要企業における閉経後骨粗鬆症治療のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Teva Pharmaceuticals Industries Ltd.、 Pfizer Inc.、 Merck & Co.、 Novartis AG、 Eli Lilly and Company、 AbbVie (Allergan plc.)、 F. Hoffmann-La Roche Ltd.、 Cipla Inc.、 Amgen Inc.

*************************************************************

・調査・分析レポートの概要
閉経後骨粗鬆症治療市場の定義
市場セグメント
世界の閉経後骨粗鬆症治療市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の閉経後骨粗鬆症治療市場規模
世界の閉経後骨粗鬆症治療市場規模：2022年 VS 2029年
世界の閉経後骨粗鬆症治療市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの閉経後骨粗鬆症治療の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の閉経後骨粗鬆症治療製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：ビスホスホネート、ビタミンD3、エストロゲンアゴニスト/アンタゴニスト、ホルモン補充療法、副甲状腺ホルモン療法、その他
閉経後骨粗鬆症治療のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院薬局、小売薬局、その他
閉経後骨粗鬆症治療の用途別グローバル売上・予測

・地域別市場分析
地域別閉経後骨粗鬆症治療市場規模 2022年と2029年
地域別閉経後骨粗鬆症治療売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Teva Pharmaceuticals Industries Ltd.、 Pfizer Inc.、 Merck & Co.、 Novartis AG、 Eli Lilly and Company、 AbbVie (Allergan plc.)、 F. Hoffmann-La Roche Ltd.、 Cipla Inc.、 Amgen Inc.
...

This research report provides a comprehensive analysis of the Postmenopausal Osteoporosis Treatment market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Postmenopausal Osteoporosis Treatment market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Postmenopausal Osteoporosis Treatment, challenges faced by the industry, and potential opportunities for market players.
The global Postmenopausal Osteoporosis Treatment market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Postmenopausal Osteoporosis Treatment market presents opportunities for various stakeholders, including Hospital Pharmacies, Retail Pharmacies. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Postmenopausal Osteoporosis Treatment market. Additionally, the growing consumer demand present avenues for market expansion.
The global Postmenopausal Osteoporosis Treatment market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Key Features:
The research report on the Postmenopausal Osteoporosis Treatment market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Postmenopausal Osteoporosis Treatment market.
Market Overview: The report provides a comprehensive overview of the Postmenopausal Osteoporosis Treatment market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Bisphosphonates, Vitamin D3), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Postmenopausal Osteoporosis Treatment market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Postmenopausal Osteoporosis Treatment market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Postmenopausal Osteoporosis Treatment market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Postmenopausal Osteoporosis Treatment market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Postmenopausal Osteoporosis Treatment market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Postmenopausal Osteoporosis Treatment market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Postmenopausal Osteoporosis Treatment, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Postmenopausal Osteoporosis Treatment market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Postmenopausal Osteoporosis Treatment market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Bisphosphonates
Vitamin D3
Estrogen Agonist/Antagonist
Hormone Replacement Therapy
Parathyroid Hormone Therapy
Others
Market segment by Application
Hospital Pharmacies
Retail Pharmacies
Others
Global Postmenopausal Osteoporosis Treatment Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Teva Pharmaceuticals Industries Ltd.
Pfizer Inc.
Merck & Co.
Novartis AG
Eli Lilly and Company
AbbVie (Allergan plc.)
F. Hoffmann-La Roche Ltd.
Cipla Inc.
Amgen Inc.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Postmenopausal Osteoporosis Treatment, market overview.
Chapter 2: Global Postmenopausal Osteoporosis Treatment market size in revenue.
Chapter 3: Detailed analysis of Postmenopausal Osteoporosis Treatment company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Postmenopausal Osteoporosis Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Introduction to Research & Analysis Reports
1.1 Postmenopausal Osteoporosis Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Postmenopausal Osteoporosis Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Postmenopausal Osteoporosis Treatment Overall Market Size
2.1 Global Postmenopausal Osteoporosis Treatment Market Size: 2022 VS 2029
2.2 Global Postmenopausal Osteoporosis Treatment Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Postmenopausal Osteoporosis Treatment Players in Global Market
3.2 Top Global Postmenopausal Osteoporosis Treatment Companies Ranked by Revenue
3.3 Global Postmenopausal Osteoporosis Treatment Revenue by Companies
3.4 Top 3 and Top 5 Postmenopausal Osteoporosis Treatment Companies in Global Market, by Revenue in 2022
3.5 Global Companies Postmenopausal Osteoporosis Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Postmenopausal Osteoporosis Treatment Players in Global Market
3.6.1 List of Global Tier 1 Postmenopausal Osteoporosis Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Postmenopausal Osteoporosis Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Postmenopausal Osteoporosis Treatment Market Size Markets, 2022 & 2029
4.1.2 Bisphosphonates
4.1.3 Vitamin D3
4.1.4 Estrogen Agonist/Antagonist
4.1.5 Hormone Replacement Therapy
4.1.6 Parathyroid Hormone Therapy
4.1.7 Others
4.2 By Type – Global Postmenopausal Osteoporosis Treatment Revenue & Forecasts
4.2.1 By Type – Global Postmenopausal Osteoporosis Treatment Revenue, 2018-2023
4.2.2 By Type – Global Postmenopausal Osteoporosis Treatment Revenue, 2024-2029
4.2.3 By Type – Global Postmenopausal Osteoporosis Treatment Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Postmenopausal Osteoporosis Treatment Market Size, 2022 & 2029
5.1.2 Hospital Pharmacies
5.1.3 Retail Pharmacies
5.1.4 Others
5.2 By Application – Global Postmenopausal Osteoporosis Treatment Revenue & Forecasts
5.2.1 By Application – Global Postmenopausal Osteoporosis Treatment Revenue, 2018-2023
5.2.2 By Application – Global Postmenopausal Osteoporosis Treatment Revenue, 2024-2029
5.2.3 By Application – Global Postmenopausal Osteoporosis Treatment Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Postmenopausal Osteoporosis Treatment Market Size, 2022 & 2029
6.2 By Region – Global Postmenopausal Osteoporosis Treatment Revenue & Forecasts
6.2.1 By Region – Global Postmenopausal Osteoporosis Treatment Revenue, 2018-2023
6.2.2 By Region – Global Postmenopausal Osteoporosis Treatment Revenue, 2024-2029
6.2.3 By Region – Global Postmenopausal Osteoporosis Treatment Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Postmenopausal Osteoporosis Treatment Revenue, 2018-2029
6.3.2 US Postmenopausal Osteoporosis Treatment Market Size, 2018-2029
6.3.3 Canada Postmenopausal Osteoporosis Treatment Market Size, 2018-2029
6.3.4 Mexico Postmenopausal Osteoporosis Treatment Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Postmenopausal Osteoporosis Treatment Revenue, 2018-2029
6.4.2 Germany Postmenopausal Osteoporosis Treatment Market Size, 2018-2029
6.4.3 France Postmenopausal Osteoporosis Treatment Market Size, 2018-2029
6.4.4 U.K. Postmenopausal Osteoporosis Treatment Market Size, 2018-2029
6.4.5 Italy Postmenopausal Osteoporosis Treatment Market Size, 2018-2029
6.4.6 Russia Postmenopausal Osteoporosis Treatment Market Size, 2018-2029
6.4.7 Nordic Countries Postmenopausal Osteoporosis Treatment Market Size, 2018-2029
6.4.8 Benelux Postmenopausal Osteoporosis Treatment Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Postmenopausal Osteoporosis Treatment Revenue, 2018-2029
6.5.2 China Postmenopausal Osteoporosis Treatment Market Size, 2018-2029
6.5.3 Japan Postmenopausal Osteoporosis Treatment Market Size, 2018-2029
6.5.4 South Korea Postmenopausal Osteoporosis Treatment Market Size, 2018-2029
6.5.5 Southeast Asia Postmenopausal Osteoporosis Treatment Market Size, 2018-2029
6.5.6 India Postmenopausal Osteoporosis Treatment Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Postmenopausal Osteoporosis Treatment Revenue, 2018-2029
6.6.2 Brazil Postmenopausal Osteoporosis Treatment Market Size, 2018-2029
6.6.3 Argentina Postmenopausal Osteoporosis Treatment Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Postmenopausal Osteoporosis Treatment Revenue, 2018-2029
6.7.2 Turkey Postmenopausal Osteoporosis Treatment Market Size, 2018-2029
6.7.3 Israel Postmenopausal Osteoporosis Treatment Market Size, 2018-2029
6.7.4 Saudi Arabia Postmenopausal Osteoporosis Treatment Market Size, 2018-2029
6.7.5 UAE Postmenopausal Osteoporosis Treatment Market Size, 2018-2029
7 Postmenopausal Osteoporosis Treatment Companies Profiles
7.1 Teva Pharmaceuticals Industries Ltd.
7.1.1 Teva Pharmaceuticals Industries Ltd. Company Summary
7.1.2 Teva Pharmaceuticals Industries Ltd. Business Overview
7.1.3 Teva Pharmaceuticals Industries Ltd. Postmenopausal Osteoporosis Treatment Major Product Offerings
7.1.4 Teva Pharmaceuticals Industries Ltd. Postmenopausal Osteoporosis Treatment Revenue in Global Market (2018-2023)
7.1.5 Teva Pharmaceuticals Industries Ltd. Key News & Latest Developments
7.2 Pfizer Inc.
7.2.1 Pfizer Inc. Company Summary
7.2.2 Pfizer Inc. Business Overview
7.2.3 Pfizer Inc. Postmenopausal Osteoporosis Treatment Major Product Offerings
7.2.4 Pfizer Inc. Postmenopausal Osteoporosis Treatment Revenue in Global Market (2018-2023)
7.2.5 Pfizer Inc. Key News & Latest Developments
7.3 Merck & Co.
7.3.1 Merck & Co. Company Summary
7.3.2 Merck & Co. Business Overview
7.3.3 Merck & Co. Postmenopausal Osteoporosis Treatment Major Product Offerings
7.3.4 Merck & Co. Postmenopausal Osteoporosis Treatment Revenue in Global Market (2018-2023)
7.3.5 Merck & Co. Key News & Latest Developments
7.4 Novartis AG
7.4.1 Novartis AG Company Summary
7.4.2 Novartis AG Business Overview
7.4.3 Novartis AG Postmenopausal Osteoporosis Treatment Major Product Offerings
7.4.4 Novartis AG Postmenopausal Osteoporosis Treatment Revenue in Global Market (2018-2023)
7.4.5 Novartis AG Key News & Latest Developments
7.5 Eli Lilly and Company
7.5.1 Eli Lilly and Company Company Summary
7.5.2 Eli Lilly and Company Business Overview
7.5.3 Eli Lilly and Company Postmenopausal Osteoporosis Treatment Major Product Offerings
7.5.4 Eli Lilly and Company Postmenopausal Osteoporosis Treatment Revenue in Global Market (2018-2023)
7.5.5 Eli Lilly and Company Key News & Latest Developments
7.6 AbbVie (Allergan plc.)
7.6.1 AbbVie (Allergan plc.) Company Summary
7.6.2 AbbVie (Allergan plc.) Business Overview
7.6.3 AbbVie (Allergan plc.) Postmenopausal Osteoporosis Treatment Major Product Offerings
7.6.4 AbbVie (Allergan plc.) Postmenopausal Osteoporosis Treatment Revenue in Global Market (2018-2023)
7.6.5 AbbVie (Allergan plc.) Key News & Latest Developments
7.7 F. Hoffmann-La Roche Ltd.
7.7.1 F. Hoffmann-La Roche Ltd. Company Summary
7.7.2 F. Hoffmann-La Roche Ltd. Business Overview
7.7.3 F. Hoffmann-La Roche Ltd. Postmenopausal Osteoporosis Treatment Major Product Offerings
7.7.4 F. Hoffmann-La Roche Ltd. Postmenopausal Osteoporosis Treatment Revenue in Global Market (2018-2023)
7.7.5 F. Hoffmann-La Roche Ltd. Key News & Latest Developments
7.8 Cipla Inc.
7.8.1 Cipla Inc. Company Summary
7.8.2 Cipla Inc. Business Overview
7.8.3 Cipla Inc. Postmenopausal Osteoporosis Treatment Major Product Offerings
7.8.4 Cipla Inc. Postmenopausal Osteoporosis Treatment Revenue in Global Market (2018-2023)
7.8.5 Cipla Inc. Key News & Latest Developments
7.9 Amgen Inc.
7.9.1 Amgen Inc. Company Summary
7.9.2 Amgen Inc. Business Overview
7.9.3 Amgen Inc. Postmenopausal Osteoporosis Treatment Major Product Offerings
7.9.4 Amgen Inc. Postmenopausal Osteoporosis Treatment Revenue in Global Market (2018-2023)
7.9.5 Amgen Inc. Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Postmenopausal Osteoporosis Treatment Market Opportunities & Trends in Global Market
Table 2. Postmenopausal Osteoporosis Treatment Market Drivers in Global Market
Table 3. Postmenopausal Osteoporosis Treatment Market Restraints in Global Market
Table 4. Key Players of Postmenopausal Osteoporosis Treatment in Global Market
Table 5. Top Postmenopausal Osteoporosis Treatment Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Postmenopausal Osteoporosis Treatment Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Postmenopausal Osteoporosis Treatment Revenue Share by Companies, 2018-2023
Table 8. Global Companies Postmenopausal Osteoporosis Treatment Product Type
Table 9. List of Global Tier 1 Postmenopausal Osteoporosis Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Postmenopausal Osteoporosis Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Postmenopausal Osteoporosis Treatment Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Postmenopausal Osteoporosis Treatment Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Postmenopausal Osteoporosis Treatment Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Postmenopausal Osteoporosis Treatment Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Postmenopausal Osteoporosis Treatment Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Postmenopausal Osteoporosis Treatment Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2024-2029
Table 30. Teva Pharmaceuticals Industries Ltd. Company Summary
Table 31. Teva Pharmaceuticals Industries Ltd. Postmenopausal Osteoporosis Treatment Product Offerings
Table 32. Teva Pharmaceuticals Industries Ltd. Postmenopausal Osteoporosis Treatment Revenue (US$, Mn) & (2018-2023)
Table 33. Teva Pharmaceuticals Industries Ltd. Key News & Latest Developments
Table 34. Pfizer Inc. Company Summary
Table 35. Pfizer Inc. Postmenopausal Osteoporosis Treatment Product Offerings
Table 36. Pfizer Inc. Postmenopausal Osteoporosis Treatment Revenue (US$, Mn) & (2018-2023)
Table 37. Pfizer Inc. Key News & Latest Developments
Table 38. Merck & Co. Company Summary
Table 39. Merck & Co. Postmenopausal Osteoporosis Treatment Product Offerings
Table 40. Merck & Co. Postmenopausal Osteoporosis Treatment Revenue (US$, Mn) & (2018-2023)
Table 41. Merck & Co. Key News & Latest Developments
Table 42. Novartis AG Company Summary
Table 43. Novartis AG Postmenopausal Osteoporosis Treatment Product Offerings
Table 44. Novartis AG Postmenopausal Osteoporosis Treatment Revenue (US$, Mn) & (2018-2023)
Table 45. Novartis AG Key News & Latest Developments
Table 46. Eli Lilly and Company Company Summary
Table 47. Eli Lilly and Company Postmenopausal Osteoporosis Treatment Product Offerings
Table 48. Eli Lilly and Company Postmenopausal Osteoporosis Treatment Revenue (US$, Mn) & (2018-2023)
Table 49. Eli Lilly and Company Key News & Latest Developments
Table 50. AbbVie (Allergan plc.) Company Summary
Table 51. AbbVie (Allergan plc.) Postmenopausal Osteoporosis Treatment Product Offerings
Table 52. AbbVie (Allergan plc.) Postmenopausal Osteoporosis Treatment Revenue (US$, Mn) & (2018-2023)
Table 53. AbbVie (Allergan plc.) Key News & Latest Developments
Table 54. F. Hoffmann-La Roche Ltd. Company Summary
Table 55. F. Hoffmann-La Roche Ltd. Postmenopausal Osteoporosis Treatment Product Offerings
Table 56. F. Hoffmann-La Roche Ltd. Postmenopausal Osteoporosis Treatment Revenue (US$, Mn) & (2018-2023)
Table 57. F. Hoffmann-La Roche Ltd. Key News & Latest Developments
Table 58. Cipla Inc. Company Summary
Table 59. Cipla Inc. Postmenopausal Osteoporosis Treatment Product Offerings
Table 60. Cipla Inc. Postmenopausal Osteoporosis Treatment Revenue (US$, Mn) & (2018-2023)
Table 61. Cipla Inc. Key News & Latest Developments
Table 62. Amgen Inc. Company Summary
Table 63. Amgen Inc. Postmenopausal Osteoporosis Treatment Product Offerings
Table 64. Amgen Inc. Postmenopausal Osteoporosis Treatment Revenue (US$, Mn) & (2018-2023)
Table 65. Amgen Inc. Key News & Latest Developments
List of Figures
Figure 1. Postmenopausal Osteoporosis Treatment Segment by Type in 2022
Figure 2. Postmenopausal Osteoporosis Treatment Segment by Application in 2022
Figure 3. Global Postmenopausal Osteoporosis Treatment Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Postmenopausal Osteoporosis Treatment Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Postmenopausal Osteoporosis Treatment Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Postmenopausal Osteoporosis Treatment Revenue in 2022
Figure 8. By Type - Global Postmenopausal Osteoporosis Treatment Revenue Market Share, 2018-2029
Figure 9. By Application - Global Postmenopausal Osteoporosis Treatment Revenue Market Share, 2018-2029
Figure 10. By Type - Global Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Postmenopausal Osteoporosis Treatment Revenue Market Share, 2018-2029
Figure 12. By Application - Global Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Postmenopausal Osteoporosis Treatment Revenue Market Share, 2018-2029
Figure 14. By Region - Global Postmenopausal Osteoporosis Treatment Revenue Market Share, 2018-2029
Figure 15. By Country - North America Postmenopausal Osteoporosis Treatment Revenue Market Share, 2018-2029
Figure 16. US Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Postmenopausal Osteoporosis Treatment Revenue Market Share, 2018-2029
Figure 20. Germany Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2018-2029
Figure 21. France Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Postmenopausal Osteoporosis Treatment Revenue Market Share, 2018-2029
Figure 28. China Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2018-2029
Figure 32. India Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Postmenopausal Osteoporosis Treatment Revenue Market Share, 2018-2029
Figure 34. Brazil Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Postmenopausal Osteoporosis Treatment Revenue Market Share, 2018-2029
Figure 37. Turkey Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Postmenopausal Osteoporosis Treatment Revenue, (US$, Mn), 2018-2029
Figure 41. Teva Pharmaceuticals Industries Ltd. Postmenopausal Osteoporosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Pfizer Inc. Postmenopausal Osteoporosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Merck & Co. Postmenopausal Osteoporosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Novartis AG Postmenopausal Osteoporosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Eli Lilly and Company Postmenopausal Osteoporosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. AbbVie (Allergan plc.) Postmenopausal Osteoporosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. F. Hoffmann-La Roche Ltd. Postmenopausal Osteoporosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Cipla Inc. Postmenopausal Osteoporosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Amgen Inc. Postmenopausal Osteoporosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 卵巣炎用治療のグローバル市場展望 2023年-2029年：薬物療法、ホルモン補充療法、手術、その他
  • 皮膚糸状菌症治療のグローバル市場展望 2023年-2029年：Rx、OTC
  • サラセミア治療のグローバル市場展望 2023年-2029年：DFO、DFP、DFX、その他
  • 呼吸器疾患治療のグローバル市場展望 2023年-2029年：吸入＆点鼻薬、経口薬、その他
  • レストレスレッグス症候群治療のグローバル市場展望 2023年-2029年：一次性レストレスレッグス症候群、二次性レストレスレッグス症候群
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MMG23DC16196 )"閉経後骨粗鬆症治療のグローバル市場展望 2023年-2029年：ビスホスホネート、ビタミンD3、エストロゲンアゴニスト/アンタゴニスト、ホルモン補充療法、副甲状腺ホルモン療法、その他" (英文：Postmenopausal Osteoporosis Treatment Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。